ALNYLAM PHARMACEUTICALS, INC. Deferred Revenue 2009-2025 | ALNY
What is deferred revenue?
Deferred revenue represents payments received in advance for goods or services that have not yet been delivered to customers.
What is ALNYLAM PHARMACEUTICALS, INC.'s current deferred revenue?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual deferred revenue for 2025 was $4.8M, a 91.27% decline from 2024. ALNYLAM PHARMACEUTICALS, INC. deferred revenue for the quarter ending December 31, 2025 was $4.8M.
What was ALNYLAM PHARMACEUTICALS, INC.'s deferred revenue in 2024?
ALNYLAM PHARMACEUTICALS, INC. annual deferred revenue for 2024 was $55.5M, a 46.01% decline from 2023.
What was ALNYLAM PHARMACEUTICALS, INC.'s deferred revenue in 2023?
ALNYLAM PHARMACEUTICALS, INC. annual deferred revenue for 2023 was $102.8M, a 144.04% increase from 2022.
What is ALNYLAM PHARMACEUTICALS, INC.'s 5-year deferred revenue CAGR?
ALNYLAM PHARMACEUTICALS, INC. deferred revenue grew at a compound annual growth rate (CAGR) of 47.98% from FY2020 to FY2025, going from $127.2M to $4.8M over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $4.8M | -91.3% | 10-K |
| FY2024 | $55.5M | -46.0% | 10-K |
| FY2023 | $102.8M | +144.0% | 10-K |
| FY2022 | $42.1M | -71.8% | 10-K |
| FY2021 | $149.5M | +17.5% | 10-K |
| FY2020 | $127.2M | +63.5% | 10-K |
| FY2019 | $77.8M | +2126.0% | 10-K |
| FY2018 | $3.5M | -91.6% | 10-K |
| FY2017 | $41.7M | +24.3% | 10-K |
| FY2016 | $33.5M | +118.5% | 10-K |
| FY2015 | $15.4M | -35.7% | 10-K |
| FY2014 | $23.9M | -27.0% | 10-K |
| FY2013 | $32.7M | +4.1% | 10-K |
| FY2012 | $31.4M | -49.6% | 10-K |
| FY2011 | $62.4M | -23.1% | 10-K |
| FY2010 | $81.1M | -1.0% | 10-K |
| FY2009 | $81.9M | - | 10-K |